Tekla Capital Management’s Verona Pharma VRNA Stock Holding History

Tekla Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-751,905	Closed	-$3.15M	–	183
2022 Q2	$3.15M	Hold	751,905	–	–	0.12%	102
2022 Q1	$3.75M	Hold	751,905	–	–	0.13%	103
2021 Q4	$5.05M	Hold	751,905	–	–	0.16%	100
2021 Q3	$4.12M	Hold	751,905	–	–	0.13%	113
2021 Q2	$4.92M	Hold	751,905	–	–	0.16%	119
2021 Q1	$6.29M	Hold	751,905	–	–	0.22%	104
2020 Q4	$5.26M	Buy	751,905 +276,503	+58%	+$1.87M	0.18%	116
2020 Q3	$2.97M	Buy	475,402 +222,223	+88%	+$1.54M	0.11%	133
2020 Q2	$1.18M	Hold	253,179	–	–	0.05%	188
2020 Q1	$1.04M	Sell	253,179 -21,821	-8%	-$120K	0.05%	174
2019 Q4	$1.58M	Hold	275,000	–	–	0.06%	160
2019 Q3	$1.26M	Hold	275,000	–	–	0.05%	150
2019 Q2	$1.47M	Hold	275,000	–	–	0.06%	145
2019 Q1	$1.72M	Hold	275,000	–	–	0.07%	138
2018 Q4	$2.48M	Hold	275,000	–	–	0.11%	118
2018 Q3	$3.44M	Hold	275,000	–	–	0.12%	115
2018 Q2	$3.78M	Hold	275,000	–	–	0.14%	106
2018 Q1	$5.5M	Hold	275,000	–	–	0.21%	88
2017 Q4	$3.28M	Hold	275,000	–	–	0.13%	106
2017 Q3	$4.22M	Hold	275,000	–	–	0.15%	93
2017 Q2	$3.21M	Buy	+275,000	New	+$3.64M	0.12%	98

Other funds holding VRNA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Tekla Capital Management's VRNA Position: Q3 2022 in Review

Tekla Capital Management sold out of Verona Pharma (VRNA) in Q3 2022, closing a stake of 751,905 shares — an estimated $3.15M sold.

Tekla Capital Management first reported a position in VRNA in Q2 2017 and held it in 21 quarters. The position peaked at $6.29M in Q1 2021. 68 funds tracked by Wall St. Rank hold VRNA as of Q3 2022.

Tekla Capital Management reported no remaining Verona Pharma position as of Q3 2022 after selling out during the quarter.
Tekla Capital Management sold 751,905 Verona Pharma shares in Q3 2022, an estimated $3.15M.
Tekla Capital Management first reported a position in Verona Pharma in Q2 2017 and held it in 21 quarters.
Tekla Capital Management's Verona Pharma position peaked at $6.29M in Q1 2021.
68 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2022.

Based on Tekla Capital Management's 13F filing for Q3 2022, filed 1 Nov 2022.